Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 254.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 468 shares of the specialty pharmaceutical company’s stock after acquiring an additional 336 shares during the quarter. Newbridge Financial Services Group Inc.’s holdings in Jazz Pharmaceuticals were worth $58,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Cape Investment Advisory Inc. increased its holdings in shares of Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 292 shares during the last quarter. Covestor Ltd increased its position in Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 345 shares during the last quarter. Headinvest LLC purchased a new position in Jazz Pharmaceuticals during the third quarter worth about $56,000. Assetmark Inc. grew its stake in shares of Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 119 shares during the period. Finally, V Square Quantitative Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 63.9% during the 4th quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company’s stock worth $84,000 after buying an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $1.07 during mid-day trading on Tuesday, hitting $113.46. 66,088 shares of the company were exchanged, compared to its average volume of 676,024. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 1.73 and a beta of 0.62. The stock has a 50 day simple moving average of $109.31 and a 200-day simple moving average of $117.47. Jazz Pharmaceuticals plc has a 1-year low of $103.01 and a 1-year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). The company had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $222.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Stifel Nicolaus lifted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Finally, Truist Financial reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $190.92.

View Our Latest Stock Analysis on JAZZ

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.40% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.